In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Jo Shorthouse

Latest From Jo Shorthouse

Coming Of Age: Pharma’s Influencer Marketing Matures

Influencer marketing has emerged as a potent tool for many industries and is a sector set to be worth $22bn in its own right by 2025.

Telehealth Ad Campaigns

Building Out A Blockbuster Franchise: AstraZeneca’s Growth Plans For US Lung Cancer Therapy

Arun Krishna reveals portfolio plans for best-selling therapy Tagrisso, and its other activities to prevent, screen and diagnose lung cancer faster.

C-Suite Speaks Business Strategies

Investment And Acquisition In Rare Diseases

In Vivo talks to investors, analysts and companies in rare disease about the challenges they face to innovate and to grow.

Rare Diseases M & A

Moving The Needle In Rare Disease: UCB’s gMG Strategy

Launching a novel drug into a new market is tough. UCB’s Kimberly Moran, talked to In Vivo about how being both patient and digital first gives the company a competitive commercial advantage in an increasingly growing market.

Rare Diseases Market Access

Win Big Or Lose Big: The Impact Of The Unified Patent Court

Decades after it was first mentioned, the updated European patent system – which includes the Unitary Patent and the Unified Patent Court – has finally materialized. What impact will this have on originator and generic pharma?

EU Legislative Reform Intellectual Property

Opportunities In Fertility: Recognizing Gaps In The Market

Ferring Pharmaceuticals’ US CSO Elizabeth Garner talks to In Vivo about the future of fertility and where investment should be heading to make a dent in this multi-million-dollar market.

Women's Health Gynecology & Urology
See All
UsernamePublicRestriction

Register